Does an endogenous methylpyridinium analogue cause Parkinson's disease?
- 1 September 1985
- journal article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 37 (9) , 679-680
- https://doi.org/10.1111/j.2042-7158.1985.tb05116.x
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Conversion of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (mptp) and its 5‐methyl analog into pyridinium saltsHelvetica Chimica Acta, 1984
- Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitorsNature, 1984
- Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonismNature, 1984
- A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.Proceedings of the National Academy of Sciences, 1983
- Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog SynthesisScience, 1983
- Conjugation Reactions of Nitrogen CentersPublished by Elsevier ,1982
- Twin study of Parkinson diseaseNeurology, 1981
- Cigarette smoking and Parkinson diseaseNeurology, 1980
- N- and O-MethylationPublished by Elsevier ,1980
- Metabolic oxidation of nicotine to chemically reactive intermediatesJournal of Medicinal Chemistry, 1979